Close

Homology Medicines Inc. (FIXX) Announces First Presentation of Data with HMI-203 In Vivo Gene Therapy Development Candidate for Hunter Syndrome

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/20/2024

1. NFLX
2. TSM
3. ISRG
4. TSLA
5. SPY
6. INFY
7. SNV
8. SMCI
9. SLB
10. PPG


Go back to Homology Medicines Inc. (FIXX) Announces First Presentation of Data with HMI-203 In Vivo Gene Therapy Development Candidate for Hunter Syndrome

Homology Medicines Announces First Presentation of Data with HMI-203 In Vivo Gene Therapy Development Candidate for Hunter Syndrome

February 8, 2021 2:50 PM EST

- IND-Enabling Studies Demonstrated Potential of a Single I.V. Administration of HMI-203 to Address Peripheral and CNS Components of Disease -

- Data at WORLDSymposium Support Plans to Initiate a HMI-203 Phase 1/2 Clinical Trial This Year -

BEDFORD, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today the first scientific presentation of data from IND-enabling studies with its HMI-203 gene therapy development candidate for Hunter... More